Jeffrey M. Leiden
2013 - Vertex Pharmaceuticals
In 2013, Jeffrey M. Leiden earned a total compensation of $13.1M as Chairman, President & CEO at Vertex Pharmaceuticals, a 132% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $2,772,000 |
|---|---|
| Option Awards | $7,529,374 |
| Salary | $1,038,462 |
| Stock Awards | $1,773,963 |
| Other | $12,675 |
| Total | $13,126,474 |
Leiden received $7.5M in option awards, accounting for 57% of the total pay in 2013.
Leiden also received $2.8M in non-equity incentive plan, $1M in salary, $1.8M in stock awards and $12.7K in other compensation.
Rankings
In 2013, Jeffrey M. Leiden's compensation ranked 231st out of 12,286 executives tracked by ExecPay. In other words, Leiden earned more than 98.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 231 out of 12,286 | 98th |
Division Manufacturing | 74 out of 4,614 | 98th |
Major group Chemicals And Allied Products | 20 out of 1,466 | 99th |
Industry group Drugs | 13 out of 1,160 | 99th |
Industry Pharmaceutical Preparations | 11 out of 890 | 99th |
Source: SEC filing on April 29, 2016.
Leiden's colleagues
We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2013.